Serina Therapeutics (SER) Operating Margin (2018 - 2025)
Serina Therapeutics' (SER) quarterly Operating Margin came in at 4280.77% in Q2 2025, up 329962.0% year-over-year from N/an in Q2 2024, and down 110.8% quarter-over-quarter from 39635.71% in Q4 2024.
Powered by 
Analysis
Serina Therapeutics (SER) Operating Margin (2018 - 2025) Analysis & Trends
Serina Therapeutics has disclosed Operating Margin across 8 years of filings, most recently posting 4280.77% for Q2 2025.
- In Q2 2025, Operating Margin rose 329962.0% year-over-year to 4280.77%; the TTM figure through Jun 2026 stood at 19190.77% (down 204923.0% YoY), while the FY2025 annual figure was 18478.46%, up 1196440.0% from the prior year.
- Operating Margin came in at 4280.77% for Q2 2025 at Serina Therapeutics, down from 39635.71% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 39635.71% in Q4 2024 to a low of 46420.0% in Q1 2024.
- Average Operating Margin over 5 years is 11810.46%, with a median of 7277.7% recorded in 2021.
- The largest YoY upside for Operating Margin was 3962791 bps in 2024 against a maximum downside of 4321333 bps in 2024.
- Over 5 years, Operating Margin stood at 6975.0% in 2021, then sank by 219 bps to 22275.0% in 2022, then surged by 100 bps to 7.81% in 2023, then surged by 507599 bps to 39635.71% in 2024, then slumped by 111 bps to 4280.77% in 2025.
- Per Business Quant data, the three most recent Operating Margin figures were 4280.77% in Q2 2025, 39635.71% in Q4 2024, and 37942.86% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Serina Therapeutics | 40.47 Mn | 17.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -4,280.77% |
| Dec 31, 2024 | 39,635.71% |
| Sep 30, 2024 | -37,942.86% |
| Jun 30, 2024 | -7,580.39% |
| Mar 31, 2024 | -46,420.00% |
| Dec 31, 2023 | 7.81% |
| Sep 30, 2023 | -5,044.83% |
| Jun 30, 2023 | -13,500.00% |
| Mar 31, 2023 | -3,206.67% |
| Dec 31, 2022 | -22,275.00% |
| Sep 30, 2022 | -17,222.22% |
| Jun 30, 2022 | -13,258.33% |
| Mar 31, 2022 | -41,040.00% |
| Sep 30, 2021 | -6,975.00% |
| Jun 30, 2021 | -5,959.46% |
| Mar 31, 2021 | -3,905.36% |
| Dec 31, 2020 | -1,472.78% |
| Sep 30, 2020 | -3,473.91% |
| Jun 30, 2020 | -5,262.22% |
| Mar 31, 2020 | -3,379.78% |